A detailed history of Two Sigma Investments, LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 828,490 shares of CCCC stock, worth $3.36 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
828,490
Previous 1,307,733 36.65%
Holding current value
$3.36 Million
Previous $6.04 Million 21.83%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.43 - $7.38 $2.12 Million - $3.54 Million
-479,243 Reduced 36.65%
828,490 $4.72 Million
Q2 2024

Aug 14, 2024

BUY
$4.05 - $8.1 $550,366 - $1.1 Million
135,893 Added 11.6%
1,307,733 $6.04 Million
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $6.21 Million - $12.9 Million
1,171,840 New
1,171,840 $9.57 Million
Q3 2023

Nov 14, 2023

SELL
$1.81 - $3.89 $301,459 - $647,887
-166,552 Reduced 29.27%
402,527 $748,000
Q2 2023

Aug 14, 2023

BUY
$2.75 - $3.77 $840,991 - $1.15 Million
305,815 Added 116.16%
569,079 $1.56 Million
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $449,465 - $1.31 Million
144,989 Added 122.59%
263,264 $826,000
Q4 2022

Feb 14, 2023

SELL
$5.42 - $10.24 $419,963 - $793,436
-77,484 Reduced 39.58%
118,275 $697,000
Q3 2022

Nov 14, 2022

SELL
$8.03 - $12.77 $1.11 Million - $1.76 Million
-138,132 Reduced 41.37%
195,759 $1.72 Million
Q2 2022

Aug 15, 2022

BUY
$5.06 - $26.46 $1.11 Million - $5.79 Million
218,960 Added 190.51%
333,891 $2.52 Million
Q1 2022

May 16, 2022

BUY
$19.99 - $33.23 $2.3 Million - $3.82 Million
114,931 New
114,931 $2.79 Million
Q4 2021

Feb 14, 2022

SELL
$29.39 - $46.86 $619,335 - $987,480
-21,073 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $362,690 - $510,050
10,100 Added 92.04%
21,073 $942,000
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $333,469 - $462,841
10,973 New
10,973 $415,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $198M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.